Raystone Capital

Raystone Capital's stated strategy covers buyout, early-stage (seed and start-up), expansion and late-stage growth, venture, and pre-IPO rounds. The firm's website lists these stages without indicating a primary allocation, suggesting a flexible mandate that can follow companies from inception to just before public listing.

Verified portfolio companies point to semiconductor design (ETA Semiconductor), advanced materials and specialty polymers (Jufeng New Materials), and medical devices (Guangzhou Weishi Bo). A 2022 ChinaVenture ranking also places the firm among the top-20 enterprise-services investors in China, indicating a dedicated enterprise-software focus.

All four listed offices are in mainland China: Beijing (headquarters), Shanghai, Guangzhou, and Hohhot. No disclosed presence or portfolio companies outside China appear in the available sourcing.

Raystone's four-office structure — spanning Beijing, the Yangtze Delta, the Pearl River Delta, and Inner Mongolia — suggests a regional sourcing model rather than concentration in a single tech hub. The firm has not publicly described its origination process, but the geographic spread implies relationships across both coastal innovation centers and inland industrial economies.

Raystone is classified as an asset manager and private equity firm. It does not present itself as a family office, and its website frames it as an institutional investor raising capital from limited partners, referenced under 'Investor Relations — Our Investors'.